The BioPharm America conference will again be held in Boston, this time from Sept. 17–19 at the Westin Boston Waterfront, EBD Group and the Massachusetts Biotechnology Council (a.k.a. MassBio) announced Thursday.
Last year’s event drew more than 750 delegates representing 462 companies from 30 countries, EBD Group and MassBio said in a press release.
At the upcoming conference, attendees will include representatives from such companies as AstraZeneca, Bayer HealthCare, EMD Serono, Janssen, Merck, Novo Nordisk, and Shire, the event’s organizers said.
“Boston is a biotechnology innovation hub. There are more than 500 companies focused on pharmaceutical and biotech drug discovery located in Massachusetts, from small start-ups to large established pharmaceuticals,” Carola Schropp, president of EBD Group, said in a statement. “This creates an ideal environment for partnering, and is what draws the global biotech sector to BioPharm America.”
MassBio is a not-for-profit trade organization that represents the Massachusetts biotechnology industry.
“BioPharm America is the forum that enables regional biotech companies to identify and enter into strategic relationships at the global level,” MassBio CEO Robert Coughlin said in a statement. “The partnering at BioPharm America, and particularly the process of meeting face-to-face to discuss novel assets, is a definite advantage in the culmination of any deal.”